Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Viventia posts promising cancer data
The study, which was conducted in Brazil, enrolled 20 patients who had advanced head and neck cancer and continuing disease progression, with all patients having failed previous courses
The study, which was conducted in Brazil, enrolled 20 patients who had advanced head and neck cancer and continuing disease progression, with all patients having failed previous courses
A total of 33 patients have been enrolled in this study, with 27 patients included in the highest dose group, where they receive an initial dose of 500mg
The study is designed to evaluate the safety, tolerability and pharmacokinetics of single doses of up to six levels of AEOL 10150 in patients diagnosed with amyotrophic lateral
Posurdex is an investigational, bioerodable, extended release implant that delivers dexamethasone to the targeted disease site at the back of the eye for the treatment of macular edema.
This is the first of three planned subject dosing studies that SCOLR Pharma is conducting, in support of an abbreviated new drug application (ANDA) to the FDA later
This approval expands the label to include the treatment of multiple myeloma patients who have received at least one prior therapy, and thus doubles the number of patients
The fast track programs of the FDA are designed to facilitate the development and expedite the review of new drugs intended for serious or life-threatening conditions and demonstrating
WinRho SDF is used to treat immune thrombocytopenic purpura (ITP), a critical autoimmune bleeding disorder. Baxter currently markets WinRho SDF for Cangene in the UK and intends to
The phase I clinical study is designed as an open label single dose escalation safety study in patients with chemo-refractive ovarian cancer. MORAb-003 is a monoclonal antibody that
The age-related macular degeneration (AMD) research initiative will be led by Dr Gregory Hageman, professor at the UI Carver College of Medicine. “The molecular events leading to the